

Brain white matter pathways of resilience to chronic back pain: a multisite validation

Reviewed Preprint

Published from the original preprint after peer review and assessment by eLife.

About eLife's process

Reviewed preprint version 1

April 3, 2024 (this version)

Posted to preprint server

February 1, 2024

Sent for peer review

January 30, 2024

Mina Mišić , Noah Lee, Francesca Zidda, Kyungjin Sohn, Katrin Usai, Martin Löffler, Md Nasir Uddin, Arsalan Farooqi, Giovanni Schifitto, Zhengwu Zhang, Frauke Nees, Paul Geha, Herta Flor

Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany; • Department of Psychiatry, University of Rochester Medical Center, 14642 Rochester, NY, USA; • Department of Statistics and Operations Research, University of North Carolina, 27599 Chapel Hill, NC, USA; • Department of Experimental Psychology, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; • Department of Neurology, University of Rochester Medical Center, 14642 Rochester, NY, USA; • Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, 24105 Kiel, Germany;

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

Chronic back pain (CBP) is a global health concern with significant societal and economic burden. While various predictors of back pain chronicity have been proposed, including demographic and psychosocial factors, neuroimaging studies have shown that brain characteristics can serve as robust predictors of CBP. However, large-scale, multisite validation of these predictors is currently lacking. In two independent longitudinal studies, we examined white matter diffusion imaging data and pain characteristics in patients with subacute back pain (SBP) over six- and 12-month periods. Diffusion data from individuals with CBP and healthy controls (HC) were analyzed for comparison. Whole-brain tract-based spatial statistics analyses revealed that a cluster in the right superior longitudinal fasciculus (SLF) tract had larger fractional anisotropy (FA) values in patients who recovered (SBPr) compared to those with persistent pain (SBPp), and predicted changes in pain severity. The SLF FA values accurately classified patients at baseline and follow-up in a third publicly available dataset (Area under the Receiver Operating Curve ~ 0.70). Notably, patients who recovered had FA values larger than those of HC suggesting a potential role of SLF integrity in resilience to CBP. Structural connectivity-based models also classified SBPp and SBPr patients from the three data sets (validation accuracy 67%). Our results validate the right SLF as a robust predictor of CBP development, with potential for clinical translation. Cognitive and behavioral processes dependent on the right SLF, such as proprioception and visuospatial attention, should be analyzed in subacute stages as they could prove important for back pain chronicity.

eLife assessment

This **valuable** study provides **incomplete** evidence that white matter diffusion imaging of the right superior longitudinal fasciculus might help to develop a predictive biomarker of chronic back pain chronicity. The results are based on a discovery-replication approach with different cohorts, but the sample size is limited, and the clinical relevance is overstated. The findings will interest researchers interested in the brain mechanisms of chronic pain and in developing brain-based biomarkers of chronic pain.

Introduction

Chronic back pain (CBP) is the leading cause of disability worldwide⁽¹⁾; the annual contribution of patients with back pain to all-cause medical costs is \$365 billion in the United States alone.⁽²⁾ In 2020, there were over 500 million reported cases of prevalent low back pain globally and central Europe had the highest age-standardized rate of prevalence with 12,800 cases per 100,000 individuals.⁽³⁾ In addition, CBP is associated with significant co-morbidities such as substance misuse,⁽⁴⁾ depression,^(5–7) anxiety,^(5, 7) and obesity.^(8, 9) The large majority of CBP cases suffer from primary pain.⁽¹⁰⁾ It is estimated that 25–50 % of patients with subacute back pain (SBP, duration 6–12 weeks) go on to develop CBP.^(11–15) Once back pain is chronic, it is very difficult to treat.^(16–20) Therefore, prevention of the transition to the chronic phase⁽²¹⁾ is key to reducing the prevalence, and as a result, the burden of CBP.

Early identification of the likelihood of pain chronicity is a pre-requisite step for allowing the efficient implementation of preventive treatment⁽²²⁾ because diagnostic and treatment procedures offered to all (sub)acute back pain patients expose resilient patients to unnecessary and risky procedures. In addition, treatment offered to all patients is burdensome to the healthcare system.^(23, 24) However, validated quantitative prognostic biomarkers that can predict disease trajectory and guide treatment in back pain patients have yet to be identified.

Some studies have addressed this question with prognostic models incorporating demographic, pain-related, and psychosocial predictors.^(21, 25–27) While these models are of great value showing that few of these variables (e.g. work factors) might have significant prognostic power on the long-term outcome of back pain and provide easy-to-use brief questionnaires-based tools, ^(21, 25) parameters often explain no more than 30% of the variance^(28–30) and their prognostic accuracy is limited.⁽³¹⁾ Neurobiological measures could therefore complement existing prognostic models based on psychosocial variables to improve overall accuracy and discriminative power as well as offer a mechanistic insight into chronic pain development.

Neuroimaging research has demonstrated that structural and functional brain characteristics^(32–35) can be robust predictors of CBP. Increased prefrontal-limbic functional connectivity during episodes of heightened subacute ongoing back pain was found to be a significant predictor of CBP.⁽³²⁾ Functional changes in the same pathway related to reward learning showed predictive value in the CBP development⁽³⁶⁾ and low somatosensory cortex excitability in the acute stage of low back pain was identified as a potential cause of CBP chronicity.⁽³⁷⁾ One study so far has investigated structural changes in back pain in a longitudinal manner and found that changes across several white matter tracts including the temporal part of left superior longitudinal fasciculus, external capsule, parts of the corpus callosum, and parts of the internal capsule were predictive of back pain development at 1-year follow-up.⁽³³⁾ Despite the identification of these promising biomarkers of pain chronicity, their

validation across multiple independent cohorts remains rare.⁽³⁸⁾ Here we investigated brain white matter predictors of back pain chronicity across three independent samples originating from 3 different sites and expected white matter tracts previously found predictive of CBP⁽³³⁾ to show higher fractional anisotropy values (FA; greater structural integrity) in patients who recovered compared to those whose pain persisted. We additionally hypothesized that patients who recovered would also exhibit greater structural integrity within the prefrontal-limbic tract related to learning and memory, uncinatus fasciculus,⁽³⁹⁾ in line with findings that learning-related processes could be predictive of CBP.⁽³⁶⁾ We expected that lower FA at baseline would predict persistent state and greater pain severity at follow-up.

Results

Demographic and clinical characteristics

At baseline, the data collected in New Haven included 16 SBPr patients who recovered (SBPr) at approximately one-year follow-up as their low-back pain intensity dropped by more than 30% relative to baseline and 12 SBP patients whose pain persisted at follow-up (**Table S1**). The SBPp patients were older (38.0 ± 3.6 years, average $\pm$ SEM) and had pain for a slightly longer duration (10.8 ± 0.9 weeks) than the SBPr patients (age = 30.8 ± 2.2 years; pain duration = 8.6 ± 0.9 weeks) but these differences did not reach statistical significance (t-score (degrees of freedom) ($t(df)$) = $1.8(26)$, $p = 0.08$ for age and $t(df) = 1.8(26)$, $p = 0.08$ for duration comparisons, respectively, unpaired T-test). The groups did not significantly differ in the distribution of males and females ($\chi^2 = 0.32$, $df = 1$, $p = 0.57$) or body mass index (BMI) ($t(df) = 0.35(26)$, $p = 0.73$). They did not significantly differ in average reported pain intensity ($t(df) = -0.45(26)$, $p = 0.66$) (**Table S1**). The SBPr patients reported significantly ($p = 0.02$) larger depression scores on Beck's Depression Inventory (BDI) (7.3 ± 1.2) than the SBPp patients (3.1 ± 1.1 , $t(df) = -2.65(26)$, $p = 0.02$) but the average score indicated that the SBPr patients did not have any clinically significant symptoms (i.e., average BDI < 10).

Whole-brain Tract-Based Spatial Statistics

We calculated voxel-wise FA of each participant and performed a whole brain comparison over the white matter skeleton using permutation testing between SBPr ($n = 16$) and SBPp ($n = 12$) patients at baseline (unpaired t-test, $p < 0.05$, cluster-based thresholding) corrected for age, gender, and head displacement estimated by eddy current correction (**Fig. S2**). SBPr showed larger FA within the cluster of fibers part of the right superior longitudinal fasciculus (SLF) (MNI-coordinates of peak voxel: $x = 35$; $y = -13$; $z = 26$ mm; $t(\max) = 4.61$) (**Fig. 1**). The possibility that the observed difference between SBPr and SBPp patients was due to a difference in the amount of displacement applied during registration was ruled out (**Fig. S2**). We plotted the FA values of the same SLF region from healthy controls (HC) and CBP patients; **Fig. 1** shows FA values and their distributions for each group within the SLF cluster. SBPr patients had the largest FA values in the right SLF cluster, even larger than in HC, although this difference did not reach statistical significance ($p = 0.11$).

To test whether baseline FA values predict the change in pain severity from baseline to follow-up in the New Haven data set, we did multiple regression analysis with FA values as predictor and the percentage change in pain severity as outcome. In this model, FA values were predictive of pain severity at the one-year follow-up (adjusted $R^2 = 0.202$, $p = 0.009$). To confirm that this result was not driven by age, gender, or head motion, we entered these parameters in a new model adjusting the prediction for these covariates. FA values were still predictive of the change in pain intensity, with added variables improving the model fit (new model: adjusted $R^2 = 0.259$, $p = 0.037$; difference between models: $F(2,67) = 1.50$, $p = 0.237$). **Fig. 2** depicts the correlation between FA values in the right SLF and pain severity with higher FA values (greater structural integrity) associated with greater reduction in pain (percentage change).




Figure 1.

A whole brain comparison over the white matter skeleton between SBPr and SBPp patients at baseline and distribution of FA values for each group (New Haven data set).

Results of unpaired t-test ($p < 0.05$, 10,000 permutations) showing significantly increased FA (fractional anisotropy) in SBPr (recovered) compared to SBPp (persistent) patients within the right superior longitudinal fasciculus (SLF) in the New Haven data set. Rain clouds include boxplots and the FA data distribution for each group depicted on the right side of each boxplot. Jittered circles represent single data points, the middle line represents the median, the hinges of the boxplot the first and third quartiles, and the upper and lower whiskers $1.5 \times \text{IQR}$ (the interquartile range).




Figure 2.

Association between white matter FA values and pain severity (New Haven data set).

Higher fractional anisotropy (FA) values in the right superior longitudinal fasciculus (SLF) are associated with greater pain reduction (from baseline to follow-up) in the New Haven data set.

Validation of the results obtained from the New Haven data

Mannheim data

In another independent study, a whole-brain comparison of FA over the white matter skeleton using permutation testing (unpaired t-test, $p < 0.05$, threshold-free cluster enhancement (TFCE) corrected for age, gender, and two motion parameters (translation and rotation) revealed two clusters, one in the right superior longitudinal fasciculus (SLF) tract (cluster size = 409 voxels, MNI-coordinates of peak voxel: $x = 26$, $y = -33$, $z = 45$, $p(\text{TFCE}) = 0.041$, $t(\text{max}) = 3.57$) and one in the right corticospinal tract/superior corona radiata (cluster size = 381 voxels, MNI-coordinates of peak voxel: $x = 29$, $y = -16$, $z = 21$, $p(\text{TFCE}) = 0.041$, $t(\text{max}) = 3.63$) that were significantly greater in SBPr ($N = 28$) compared to SBPp ($N = 18$) (**Fig. 3**). In addition, two smaller clusters were also identified in the same tract of the right SLF (cluster size = 39 voxels, MNI-coordinates of peak voxel: $x = 36$, $y = -13$, $z = 34$, $p(\text{TFCE}) = 0.048$, $t(\text{max}) = 3.19$) and right corticospinal tract (cluster size = 13 voxels, MNI-coordinates of peak voxel: $x = 21$, $y = -27$, $z = 42$, $p(\text{TFCE}) = 0.049$, $t(\text{max}) = 2.41$) as significantly different between SBPr and SBPp patients. In the next step, we extracted FA values from the significant clusters of the Mannheim data and compared them across all groups at that site. As in the New Haven set, recovered patients had the largest FA values across groups, even greater than HC although this difference did not reach significance level ($p = 0.12$) (**Fig. 3**).

To test whether FA baseline values from the significantly different clusters could predict the change in pain severity from baseline to follow-up, we did multiple regression analysis with FA values as predictor and the change in pain severity percentage as outcome. In this model, FA values were predictive of pain severity at the 6-month follow-up (adjusted $R^2 = 0.120$, $p = 0.011$). To confirm that this result was not driven by age, gender, or head motion, we entered these parameters in a new model adjusting the prediction for covariates. FA values were still predictive of chronicity, with added variables improving the model fit (new model: adjusted $R^2 = 0.236$, $p = 0.007$; difference between models: $F(2,67) = 3.67$, $p = 0.046$). **Fig. 4** depicts the correlation between FA values and pain severity with higher FA values (greater structural integrity) associated with greater reduction in pain (percentage change).

We tested the accuracy of local diffusion properties of the right SLF extracted from the mask of voxels passing threshold in the New Haven data (**Fig. 1**) in classifying the Mannheim patients into persistent and recovered. We used a simple cut-off (40) for the evaluation of the area under the receiver operating characteristic (ROC) curve (AUC). FA values corrected for age, gender, and head displacement, accurately classified SBPr ($N = 28$) and SBPp ($N = 18$) patients from the Mannheim data set with an AUC = 0.66 ($p = 0.031$, tested against 10,000 random permutations, **Fig. S3A**), validating the predictive value of the right SLF cluster (**Fig. 5**).

Chicago data

To further validate the right SLF predictive power, we used the mask shown in **Fig. 1** to extract FA values from SBPr and SBPp patients available in the Chicago data set. FA values in the validation data sets were corrected for age, gender, and head displacement. The criterion for recovery was set identically to the New Haven study, requiring $\geq 30\%$ reduction of reported low-back pain intensity at one-year follow-up. FA values were calculated for two time points; one obtained at baseline when pain was still subacute (6-12 weeks), and one obtained at a one-year follow-up when pain either remitted or persisted. FA values of the right SLF (**Fig. 1**) accurately classified SBPr ($N = 23$) and SBPp ($N = 35$) patients from Chicago with an AUC = 0.70 ($p = 0.0043$, **Fig. S3B**) at baseline (**Fig. 6A**), and SBPr ($N = 28$) and SBPp ($N = 34$) patients with an AUC = 0.66 ($p = 0.014$, see **Fig. S3C**) at follow-up (**Fig. 6B**), validating the predictive cluster from the right SLF at yet another site.




Figure 3.

A whole brain comparison over the white matter skeleton between SBPr and SBPp patients at baseline and distribution of FA values for each group (*Mannheim data set*).

Results of unpaired t-test ($p < 0.05$, 10,000 permutations) showing significantly increased FA (fractional anisotropy) in SBPr (recovered) compared to SBPp (persistent) patients at six-months follow-up within the right superior longitudinal fasciculus (SLF) in the Mannheim data set. Rain clouds include boxplots and the FA data distribution for each group depicted on the right side of each boxplot. Jittered circles represent single data points, the middle line represents the median, the hinges of the boxplot the first and third quartiles, and the upper and lower whiskers $1.5 \times \text{IQR}$ (the interquartile range).




Figure 4.

Association between white matter FA values and pain severity (Mannheim data set).

Higher fractional anisotropy (FA) values in the right superior longitudinal fasciculus (SLF) are associated with greater pain reduction (from baseline to follow-up) in the Mannheim data set.




Figure 5.

Validation of the accuracy of FA in the right SLF in classifying Mannheim patients.

The right superior longitudinal fasciculus (SLF) cluster from the discovery set accurately classifies patients who recovered (SBPr) and those whose pain persisted (SBPp) in the Mannheim data set at a six-month follow-up. Classification accuracy is based on the ROC curve. Circles on the boxplots represent single data points, the middle line represents the median, the hinges of the boxplot the first and third quartiles, and the upper and lower whiskers 1.5*IQR (the interquartile range). AUC: area under the curve; * $p < 0.05$.




Figure 6.

Validation of the accuracy of FA in the right SLF in classifying Chicago patients.

The right SLF (superior longitudinal fasciculus) cluster from the discovery set accurately classifies patients who recovered (SBPr) and those whose pain persisted (SBPp) in the Chicago (OpenPain) data set at visit 1 (baseline) **(A)** and visit 2 (one-year follow-up) **(B)**. Classification accuracy is based on the ROC curve. Circles on the boxplots represent single data points, the middle line represents the median, the hinges of the boxplot the first and third quartiles, and the upper and lower whiskers 1.5*IQR (the interquartile range). AUC: area under the curve; * $p < 0.05$.

Structural Connectivity-Based Classification of SBPp and SBPr patients

We studied the structural connectivity of brain areas known to be connected by different parts of the right SLF by illustrating in 3 dimensions the white matter fibers traveling between them. Most of the visualized white matter bundles showed thinning (i.e., decreased density) in the SBPp patients when visually inspected relative to the SBPr patients (**Fig. 7**; **Fig. S4**).

The best performing structural connectivity model was based on combining 40% of the New Haven data with 100% of the Chicago data during initial training and validation and testing on the remaining 60% of the New Haven data or on the Mannheim data (**Table S6**). The average AUC (i.e., the average performance of the model) was 0.67 ± 0.03 (mean $\pm$ std) using a support vector classifier (SVC) when classifying the remainder of the New Haven sample and 0.53 ± 0.03 when classifying the Mannheim data (**Fig. S5**).

Discussion

The white matter properties of the right SLF were significantly different between SBPr and SBPp patients across three different sites: New Haven, Chicago, and Mannheim. Furthermore, SBPr patients showed larger FA values than pain-free controls in the right SLF in both the New Haven and Mannheim data sets. This suggests that this white matter property is a biomarker of resilience to pain chronicity where pain-free controls are composed of both high and low resilience individuals. Consistent with the concept of resilience, higher baseline fractional anisotropy in the right SLF predicted a greater percentage reduction in pain intensity at follow-up. A model based on whole-brain structural connectivity classified SBPp and SBPr patients across sites, although with a lower overall accuracy compared to the TBSS-based univariate approach. Despite the implication of the uncinate fasciculus in learning and memory,⁽³⁹⁾ which are important processes in the emergence of chronic pain,⁽⁴¹⁾ we did not detect any microstructural alterations in this tract. Alterations in the fiber complexity of the uncinate fasciculus were noted by⁽⁴²⁾ but not in fractional anisotropy⁽⁴³⁾ in CBP patients compared to pain-free controls. This suggests that either FA is not the appropriate measure used for studying the uncinate fasciculus in relation to pain, or that this tract is not involved in chronic aversive learning.

The SLF is a large bundle of white matter association fibers connecting occipital, temporal, and lateral parietal lobes with the ipsilateral frontal lobe.⁽⁴⁴⁾ In vivo studies in humans have anatomically subdivided the SLF into dorsal (SLF I), middle (SLF II), and ventral (SLF III) branches that run in parallel,⁽⁴⁵⁾ while the inclusion of the fourth component, the arcuate fasciculus, has been questioned by some authors due to its distinct anatomical trajectory that runs from the frontal to the temporal lobe.⁽⁴⁶⁾ The SLF is an essential anatomical substrate for major cognitive functions such as language (left SLF), memory, emotions, motor planning, and visuospatial processing.⁽⁴⁷⁾ The right SLF is particularly important in visuospatial attention to the extra-personal space and the positioning of the body in the physical space.⁽⁴⁸⁾ It connects frontal and parietal areas critical in the top-down control of attention during tasks involving any sensory modality.⁽⁴⁷⁾ The SLF cluster found in our discovery set and validated in two other independent data sets, spans all three branches of the SLF white matter tract.

Studies in patients with brain lesions have supported the importance of the right SLF in top-down attention processing. For example, patients who underwent glioma resection with damages to the right medial superior and middle frontal gyrus, brain regions traversed by SLF I and II, showed persistent visuospatial cognitive dysfunction postoperatively.⁽⁴⁹⁾ Similarly, patients with right prefrontal glioma with the resection cavity located in a region overlapping SLF I and SLF II had persistent spatial working memory deficits even in the absence of motor and language deficits.⁽⁵⁰⁾ Lesions within the SLF II have been linked to visuospatial neglect,^(51, 52) supporting




Figure 7.

Structural connectivity-based classification of SBPp and SBPr patients.

Three-dimensional illustration of parts of the SLF connecting the temporal lobe to the opercular frontal lobe **(A)**, in SBPp, (n = 12 of the New Haven data) **(B)**, and SBPr (n = 16 of the New Haven data) **(C)**. The illustrated white matter bundles are depicted in the right lateral view with the directional color code (green, anterior-posterior; blue, superior-inferior; red, left-right). Ant, anterior; post, posterior; STG, superior temporal gyrus.

the role of this subcomponent in visuospatial awareness. Together the literature on the right SLF role in higher cognitive functions suggests, therefore, that resilience to chronic pain is a top-down phenomenon related to visuospatial and body awareness.

Higher FA values in the right SLF have been associated with better performance in sustained attention in children⁽⁵³⁾ and people suffering from attention deficits or hyperactivity disorder.^(54–56) After a stroke, patients who had higher baseline FA values within SLF II showed higher success rates in the visuomotor task after 4 weeks of learning compared to those with lower baseline FA values.⁽⁵⁷⁾ Similarly, a recent study showed that SLF II underwent plastic changes after learning of tracking movement tasks requiring both top-down attentional processes and bottom-up somatosensory feedback to adjust one's own movement, and the degree of this plasticity predicted task-related success.⁽⁵⁸⁾ Since the constant adaptation of motor control in these tasks is dependent on spatial awareness and proprioception, the integrity of the SLF II appears crucial to their intact functioning. Proprioception, which is a bottom-up somatic signal closely related to visuospatial processing, is critical for recognizing one's own body position and hence the awareness of the physical self. Changes at the higher-order level of proprioceptive processing can also affect body perception.⁽⁵⁹⁾ The right SLF connects a network of brain regions involved in proprioceptive awareness and allows us to perceive ourselves as separate entities from external animate and inanimate objects.⁽⁶⁰⁾ Lesions of this white matter bundle and/or of the right parietal lobe are associated with hemispatial neglect of the left side of extra-personal space and, in extreme cases, of one's own body parts.⁽⁴⁷⁾ Specifically, SLF II and SLF III subcomponents have been linked to dysfunctions in proprioception. The inferior frontoparietal network, connected by the SLF III, showed predominant right-hemispheric activation during both the visual self-face recognition and limb proprioceptive illusion task, which suggests importance of this tract in self-awareness independent of the sensory modality and body parts involved.⁽⁶¹⁾ Similarly, changes in limb position in relation to posture activate the same network, hence suggesting that constant awareness of our body position and corrective feedback on our body schema is indeed dependent on this tract.⁽⁴⁸⁾ Although the findings on the direct association between impaired proprioception and CBP are inconclusive due to the variety of methods used to measure proprioceptive performance,^(62–64) there is evidence that the central processing of back-related proprioceptive signals is affected in chronic low back pain.^(59, 65) Indeed, it has been shown that pain perception influences body representation,⁽⁶⁶⁾ and body representation is altered in patients with chronic pain as investigated by psychophysical,^(65, 67) and neuroimaging studies.^(59, 68, 69) Interestingly, in some cases disturbances in body representation occurred before the development of chronic pain⁽⁷⁰⁾ and predicted decreased analgesic response to an exercise treatment,⁽⁷¹⁾ suggesting a causal role of such a distortion in chronicity. While we did not collect proprioceptive and attention measures in the SBP patients, our results suggest that these measures could be useful to separate resilient and at-risk patients.

The asymmetry of the functions subserved by the SLF is notable as lesions to the right but not left SLF lead to hemispatial neglect on the left side, suggesting that vulnerabilities and strength in the neural substrate mediating attention and visuospatial processing contribute to the long-term risk or resilience to chronic pain. The observation that the structural properties of such a large association fiber network predict pain chronicity also suggests that risks and vulnerabilities to chronic pain may be determined by large, distributed frontoparietal networks on the right side of the brain. Interestingly, compared to pain-free controls, low back pain patients show functional connectivity alterations in the dorsal visual stream involved in visuospatial attention and subserved by the SLF tract, but not in the ventral visual stream.⁽⁷²⁾ The results motivated us to explore different diffusion-based parameters, primarily focusing on structural connectivity. While our SVC machine learning-based model accurately classified SBPr and SBPp patients, it did not perform better than the univariate TBSS-based analysis and was worse than the latter approach in classifying the Mannheim patients. This discrepancy is most likely because whole-brain structural connectivity approaches such as PSC⁽⁷³⁾ are more sensitive to signal-to-noise ratio and site-related differences in data acquisition parameters than TBSS such as the number of directions in

the diffusion data acquisition protocol. Another explanation is that structural connectivity-based classifiers are sensitive to the heterogeneity of patients across sites because the eligibility criteria used were similar between New Haven and Chicago but different from those in Mannheim.

Our results along with previous studies suggest that resilience to chronicity of back pain may be related to the structural integrity (i.e., FA) of the right SLF. Like Mansour et al.,⁽³³⁾ we observed that SBPr patients show larger FA values than the pain-free controls while the SBPp patients show similar FA values to the CBP patients suggesting that the pain-free population is made up of high and low-risk groups (**Fig. 1**; **Fig 3**). Notably, though, the DTI-based FA results reported by Mansour et al. were on the left side of the brain. While larger datasets are required to explain this discrepancy, it does suggest that resilience to chronic pain might also be a widespread brain property involving other large-scale brain networks. CBP state has been associated with white matter changes across several tracts,⁽⁴³⁾ but here we show that the SLF tract is particularly important in the transition phase of subacute to CBP state, predicting long-term chronicity in a lateralized, right-dominant manner. As pain turns chronic, it is likely to progressively involve other neural pathways, indicating changes within broader neural networks. In fact, neural signatures of sustained and chronic pain are predominately observed in somatomotor, frontoparietal, and dorsal attention networks,⁽⁷⁴⁾ which corresponds to the microstructural changes in tracts found in the chronic state. The right SLF, however, shows changes already at half a year into chronicity, remains stable at one year, and could therefore serve as a biomarker to address the need for early detection of risk. Despite different time frames for the follow-up, initial (baseline) pain intensities (and accordingly different criteria for subgrouping SBP into SBPr/SBPp), population, sites, scanners, and pain questionnaires/screening used, we successfully validated results across three different sites. Moreover, we carefully addressed the potential confounding effects of head displacement, which can lead to either positive or negative bias⁽⁷⁵⁾ by accounting for it in the analysis. This points towards the robustness of the integrity of the SLF as a biomarker of resilience to CBP, with a great potential for clinical translation.

Limitations

Our results are based on heterogeneous samples, heterogeneous pain measures, different criteria for recovery, and different scanners across sites. We believe that the data presented here is nevertheless robust since multisite validated but needs replication. Future studies could validate our results with increased sample sizes and using the same criteria across sites. In addition, our studies did not evaluate functions subserved by the right SLF such as proprioception or other types of visuo-spatial tasks. We believe that the results strongly support the future assessment of such cognitive functions in the study of risk and resilience to chronic pain.

Conclusions and future directions

We have identified a brain white matter biomarker of resilience to CBP and validated it in multiple independent cohorts at different sites. This biomarker is easy to obtain (~10 min of scanning time) and opens the door for translation into clinical practice. Although chronic pain may eventually affect other neural networks, the microstructural changes in the right SLF tract are evident early in the course of the illness and remain stable as pain progresses. Future studies should investigate how this brain structural predisposition to CBP may impact brain function, information processing, and neural networks. This could lead to potential neural targets for early interventions such as neurofeedback⁽⁷⁶⁾ or brain stimulation⁽⁷⁷⁾. In addition, cognitive and behavioral processes associated with the right SLF, such as proprioception and attentional functions, should be examined in sub-acute stages, as targeting these processes could add to the effective prevention of chronicity. *To establish the clinical usefulness of a biomarker, it should be tested in various*

populations, settings, and contexts, and ideally be cost-effective and simple to implement.⁽³⁸⁾ In this regard, we have introduced a promising biomarker found in brain white matter, which has significant potential for clinical application in the prevention and treatment of CBP.

Materials and Methods

Data pool

New Haven (Discovery) data set

We recruited individuals in the New Haven, Connecticut area. Subjects were recruited through flyers and internet advertisements. All participants gave written informed consent to participate in the study. The study was approved by the Yale University Institutional Review Board.

Brain diffusion data were collected at baseline from 27 (12 females) subacute low-back pain patients (SBP, pain duration between 6-12 weeks), 29 (16 females) patients with chronic low-back pain (CLBP), and 28 (12 females) healthy controls (HC). One patient was excluded because of excessive head motion defined as $>3SD$ from the mean Euclidian distance of either translational or rotational displacement during the MRI scanning session and one HC subject was excluded because parts of the brain were outside the field of view.

Subjects were briefly screened at first to check (1) the location of the low-back pain, (2) if they were otherwise healthy, (3) non-smokers, and (4) pain duration (between 6 and 12 weeks for SBP and more than one year for CLBP). If they passed this initial brief screen a more detailed screen was conducted where we assessed complete medical and psychiatric history. To be included in the study, SBP subjects needed to meet the criteria of having a new-onset 6 to 12 weeks low back pain at an intensity more than 20/100 on the visual analogue scale (VAS) and report being pain-free in the year prior to the onset of back pain. CLBP patients had to have a pain duration of at least 1 year and a pain intensity of more than 30/100. Both SBP and CLBP participants had to (1) fulfill the International Association for the Study of Pain criteria for back pain,⁽⁷⁸⁾ (2) not be currently, or during the month prior to the study, on any opioid analgesics. Patients were included if their back pain was below the 12th thoracic vertebra with or without radiculopathy and was present on more days than not. SBP and CLBP diagnoses were confirmed based on history collected by an experienced clinician (P.G.). Healthy control subjects were screened likewise with, besides, the absence of any history of any pain of more than 6 weeks in duration. Participants had no history of mental disorders, chronic medical conditions (e.g., diabetes, coronary artery disease), or loss of consciousness.

The study consisted of two time points separated by approximately one year (baseline, 1-year follow-up). At each time point participants completed one testing session in the laboratory and one scanning session. Patients whose pain dropped by more than 30%⁽⁷⁹⁾ at follow-up were considered recovered, otherwise persistent. Of the SBP group, 12 patients were confirmed at follow-up as recovered subacute back pain patients (SBPr) and 16 as persistent subacute back pain patients (SBPp) and had diffusion tensor data collected. For demographic and clinical characteristics of the different groups see **Table S1**.

For the **MRI acquisition description** see **Supplementary Methods**.

Mannheim data set

Participants were recruited through advertisements in local newspapers and the website of the Central Institute of Mental Health in Mannheim, and patients were recruited additionally through the outpatient pain clinic of the Institute of Cognitive and Clinical Neuroscience, general

practitioners, and physiotherapy practices. We determined subjects' eligibility via a telephone screening form, which comprised questions about MRI contraindications, medication intake, current and previous drug/alcohol use, co-morbid medical and psychological conditions, and pain frequency and severity. All participants had to be between 18 and 70 years old to be eligible for study entry. Healthy controls had to be pain-free; patients with pain (SBP and CBP) had either low and/or upper back pain. To be included in the study, SBP participants had to have a current back pain episode of 7–12 weeks duration. Patients with a current back pain episode and additional back pain episodes in their history were included as well if the episodes never exceeded 12 weeks per year. The inclusion criteria for the CBP group were a history of back pain longer than 6 months and a current back pain episode of more than 100 days. Participants were excluded if they reported any neurological disorder, psychotic episodes, current substance abuse, a major illness, contraindication for MRI, or another painful condition as the main pain problem.

Brain diffusion data were collected at baseline from 64 patients with SBP, 24 patients with CBP, and 24 healthy controls (HC). HC and patients with CBP were matched for age and gender. Two HC, three patients with CBP, and nine patients with SBP were excluded from the analysis due to excessive head motion defined as >3SD from the mean Euclidian distance of either translational or rotational displacement during the MRI scanning session. Additionally, two SBP patients' diffusion images failed manual quality control checks due to obvious artifacts. Six patients with SBP were excluded from the analysis because they did not have interim data at follow-up. One patient with SBP was also excluded from the analysis as an outlier due to an extreme increase in pain severity from baseline to follow-up (466 percent change, $M = -15,06$; hence the subject was > 6 standard deviations from the sample mean). The final sample in the analysis comprised 22 HC, 21 patients with CBP, and 46 patients with SBP. Demographic and clinical characteristics of this data set, which was used for validation of our white matter biomarker, are presented in **Table S2**.

Medication use is presented in **Table S3**. All participants gave written informed consent to be involved in the study and received 10€/hour for their participation. The study was approved by the Ethics Committee of the Medical Faculty of Mannheim, Heidelberg University, and was conducted in accordance with the declaration of Helsinki in its most recent form.

Clinical assessments

Patients with SBP were included in the study at baseline as one group, and their pain severity was assessed at two time points (baseline, 6-month follow-up). Change in pain severity (PS) was assessed using the percentage change in the Pain Severity scale of the German version of the West Haven-Yale Multidimensional Pain Inventory(80) from baseline assessment to the follow-up screening after 6 months using the following formula: $\Delta PS = \frac{PS_{\text{follow-up}} - PS_{\text{baseline}}}{PS_{\text{baseline}}} \times 100$. Based on the pain severity percentage change, the SBP sample was divided into recovered SBP (SBPr, $N=28$), whose pain dropped by more than 20% at follow-up and persisting SBP (SBPp, $N=18$) ($\Delta PS > -20$) following criteria already published in the literature(32) (see also **Supplementary Methods**). For the **MRI acquisition description** see **Supplementary Methods**. Comorbid mental disorders are presented in **Table S4**.

For the **MRI acquisition description** see **Supplementary Methods**

Chicago data set (Open Pain)

The data set obtained through the *OpenPain.org* online database (collected in Chicago, from now on, we refer to this data set as “Chicago data set”) had 58 SBP patients (28 females) with a baseline visit (visit 1 on OpenPain, pain duration 6-12 weeks) and 60 SBP patients (29 females) with a one-year follow-up visit (visit 4 on OpenPain) on whom diffusion images were collected.

Patients were deemed recovered at one-year follow-up based on the same criterion as the New Haven data (i.e., > 30% drop in low-back pain intensity reported on the VAS). As such, we studied 35 SBPp and 23 SBPr at baseline, and 33 SBPp and 27 SBPr at follow-up. Demographic and clinical characteristics of this data set, which was used for validation of our white matter biomarker, are presented in **Table S5**. For the **MRI acquisition description** and **preprocessing of DTI Data** see **Supplementary Methods**.

Tract-Based Spatial Statistics

Voxel-wise statistical analysis of FA was carried out using Tract-Based Spatial Statistics (TBSS) (81) part of the FSL. (82) All subjects' FA data were then aligned into a common space (MNI standard 1-mm brain) using the nonlinear registration tool FNIRT, (83, 84) which uses a b-spline representation of the registration warp field. (85) Next, the mean FA image was created and thinned to create a mean FA skeleton, which represents the centers of all tracts common to the groups. Each subject's aligned FA data was then projected onto this skeleton and the resulting data fed into voxel-wise cross-subject statistics. Groups (i.e., SBPr and SBPp) were compared using unpaired t-test corrected for age, gender, and motion parameters. Head displacement was estimated by eddy current correction to extract the magnitude of translations and rotations. Overall head motion was then calculated as the Euclidian distance from head translations and rotations for each subject, and these measures were Z-transformed before they were entered into the design matrix as nuisance variables. The statistical significance of TBSS-based testing was determined using a permutation-based inference (86) where the null distribution is built using 10,000 random permutations of the groups. Significance was set at $p < 0.05$, and significant clusters were identified using threshold-free cluster enhancement. (87)

Statistical analysis

A mask formed from the significant cluster for the SBPr>SBPp contrast in the New Haven data was used to extract FA values from the Mannheim and the OpenPain data. The FA values were first corrected for confounders and then used to build a receiver operating curve (ROC) to assess classification accuracy (recovered and persistent pain patients as binary classes) based on the brain white matter data. The statistical significance of the area under the ROC (AUC) was tested against 10,000 random permutations of the group labels to generate a random distribution of the AUC values. Additionally, we tested if FA values predict pain percentage change in a dimensional approach using multiple linear regression with the FA data entered as a predictor, and pain percentage change as an outcome. In both, classification and linear regression analysis, age, gender, and motion parameters (translation and rotation) were entered as covariates of no interest.

Estimation of structural connectivity

Structural connectivity was estimated from the diffusion tensor data using a population-based structural connectome (PSC) detailed in a previous publication. (73) PSC can utilize the geometric information of streamlines, including shape, size, and location for a better parcellation-based connectome analysis. It, therefore, preserves the geometric information, which is crucial for quantifying brain connectivity and understanding variation across subjects. We have previously shown that the PSC pipeline is robust and reproducible across large data sets. (73) PSC output uses the Desikan (88) atlas of cortical and sub-cortical regions of interest (ROI). The output includes fiber count, fiber length, and fiber volume shared between the ROIs in addition to measures of fractional anisotropy and mean diffusivity.

Machine learning and cross-validation

The processing steps applied to the PSC output are summarized in **Fig. S1** and were published previously. (73) We used fiber count and total connected surface area connecting each pair of regions as the input features, which were 87 x 87 connectivity matrices; the latter two features

were chosen because of their demonstrated reliability in prior work.⁽⁷³⁾ Dimensions were reduced using tensor principal component analysis (TNPCA) with hyperparameter $K = 87$. Next, because data originated from different sites (New Haven, Chicago, and Mannheim), we applied the ComBat harmonization⁽⁸⁹⁾ to account for the effect of different sites on the data. Linear regression was used next to correct the data for age, gender, and head translation and rotation magnitudes. We used logistic regression, linear support vector classification (SVC), and random forest as our regression methods with leave-one-out cross-validation (LOOCV) and the number of components as a hyperparameter. Hence, the number of PCs included in the model was randomly chosen from a sequence of 22 numbers starting with 1 with an increment of 4 and a maximum of 87. The training of our regression models was performed using different combinations of data originating from New Haven and the Chicago database as outlined in **Table S6** and tested on the remainder of the data from these two sites or on the data originating from Mannheim. The combination of the data during model training was bootstrapped 50 times and testing and validation were repeated accordingly. We chose to train the model only on the data originating from New Haven and Chicago because the eligibility criteria were quite similar between the two sets but different from those used to recruit SBP patients at Mannheim. The average performance of our classifier was based on the models that achieved a validation area under (AUC) the receiver operating characteristic curve (ROC) of ≥ 0.75 during training.

Acknowledgements

The New Haven study was funded by the National Institute on Drug Abuse grant number K08DA037525. The Mannheim study was supported by a grant from the Deutsche Forschungsgemeinschaft (SFB1158/B03 to F.N. and H.F.) and it has been registered on the “German Clinical Trials Register” the registration ID is DRKS00008835. The access website is as follows: <https://www.drks.de/>. The OPP project (Principal Investigator: A. Vania Apkarian, Ph.D. at Northwestern University) is supported by the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Drug Abuse (NIDA).

Data availability

New Haven and Mannheim data sets are available upon reasonable request from the lead contacts (mina.kandic@zi-mannheim.de; Paul_Geha@urmc.rochester.edu), as the studies are ongoing. The imaging data set, demographical, and all clinical variables will be shared in an anonymized form to ensure participant privacy and to comply with legal requirements. The data set obtained from Chicago is from the OpenPain Project (OPP) publicly available at: <https://www.openpain.org/>.

Author Contributions

Study concept and design, H.F., F.N., P.G., and M.M.; acquisition of data, M.M., K.U., and M.L.; analysis and interpretation of data, M.M. and N.L.; drafting of the manuscript, M.M.; critical revision of the manuscript for important intellectual content, M.M., N.L., F.Z., K.S., M.L., K.U., M.N.U., A.F., G.S., Z.Z., F.N., P.G., and H.F.; obtained funding, P.G., H.F., and F.N.; administrative or technical support, M.M., F.Z., study supervision, F.N., P.G., and H.F.

References

1. Hoy D., et al. (2012) **A systematic review of the global prevalence of low back pain** *Arthritis Rheum* **64**:2028–2037
2. Lo J., Chan L., Flynn S. (2021) **A Systematic Review of the Incidence, Prevalence, Costs, and Activity and Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 Update** *Arch Phys Med Rehabil* **102**:115–131
3. Ferreira M. L., et al. (2023) **Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021** *The Lancet Rheumatology* **5**:e316–e329
4. Deyo R. A., Von Korff M., Duhrkoop D. (2015) **Opioids for low back pain** *BMJ* **350**
5. Gore M., Sadosky A., Stacey B. R., Tai K. S., Leslie D. (2012) **The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings** *Spine (Phila Pa 1976)* **37**:E668–677
6. Becker A., et al. (2010) **Low back pain in primary care: costs of care and prediction of future health care utilization** *Spine (Phila Pa 1976)* **35**:1714–1720
7. Wasan A. D., et al. (2015) **Psychiatric Comorbidity Is Associated Prospectively with Diminished Opioid Analgesia and Increased Opioid Misuse in Patients with Chronic Low Back Pain** *Anesthesiology* **123**:861–872
8. Shiri R., Karppinen J., Leino-Arjas P., Solovieva S., Viikari-Juntura E. (2010) **The association between obesity and low back pain: a meta-analysis** *Am.J.Epidemiol* **171**:135–154
9. Shiri R., Lallukka T., Karppinen J., Viikari-Juntura E. (2014) **Obesity as a risk factor for sciatica: a meta-analysis** *Am J Epidemiol* **179**:929–937
10. Finucane L. M., et al. (2020) **International Framework for Red Flags for Potential Serious Spinal Pathologies** *Journal of Orthopaedic & Sports Physical Therapy* **50**:350–372
11. Costa L. C., et al. (2009) **Prognosis for patients with chronic low back pain: inception cohort study** *BMJ* **339**
12. Stevans J. M., et al. (2021) **Risk Factors Associated With Transition From Acute to Chronic Low Back Pain in US Patients Seeking Primary Care** *JAMA Network Open* **4**:e2037371–e2037371
13. Nieminen L. K., Pyysalo L. M., Kankaanpää M. J. (2021) **Prognostic factors for pain chronicity in low back pain: a systematic review** *Pain Rep* **6**
14. Axén I., Leboeuf-Yde C. (2013) **Trajectories of low back pain** *Best Practice & Research Clinical Rheumatology* **27**:601–612
15. Price T. J., et al. (2018) **Transition to chronic pain: opportunities for novel therapeutics** *Nature Reviews Neuroscience* **19**:383–384

16. Machado L. A., Maher C. G., Herbert R. D., Clare H., McAuley J. H. (2010) **The effectiveness of the McKenzie method in addition to first-line care for acute low back pain: a randomized controlled trial** *BMC Med* **8**
17. Henschke N., et al. (2010) **Behavioural treatment for chronic low-back pain** *Cochrane Database Syst Rev* <https://doi.org/10.1002/14651858.CD002014.pub3>
18. Costa L. O., et al. (2009) **Motor control exercise for chronic low back pain: a randomized placebo-controlled trial** *Phys Ther* **89**:1275–1286
19. Wand B. M., O’Connell N. E. (2008) **Chronic non-specific low back pain - sub-groups or a single mechanism?** *BMC Musculoskelet Disord* **9**
20. da C. M. C., et al. (2012) **The prognosis of acute and persistent low-back pain: a meta-analysis** *CMAJ* **184**:E613–E624
21. Traeger A. C., et al. (2016) **Estimating the Risk of Chronic Pain: Development and Validation of a Prognostic Model (PICKUP) for Patients with Acute Low Back Pain** *PLoS Med* **13**
22. Berwick D. M., Hackbarth A. D. (2012) **Eliminating waste in US health care** *JAMA* **307**:1513–1516
23. Litkowski P. E., Smetana G. W., Zeidel M. L., Blanchard M. S. (2016) **Curbing the Urge to Image** *Am J Med* **129**:1131–1135
24. Chou R., Qaseem A., Owens D. K., Shekelle P. (2011) **P. Clinical Guidelines Committee of the American College of, Diagnostic imaging for low back pain: advice for high-value health care from the American College of Physicians** *Ann Intern Med* **154**:181–189
25. Hill J. C., et al. (2008) **A primary care back pain screening tool: identifying patient subgroups for initial treatment** *Arthritis Rheum* **59**:632–641
26. Hockings R. L., McAuley J. H., Maher C. G. (2008) **A systematic review of the predictive ability of the Orebro Musculoskeletal Pain Questionnaire** *Spine (Phila Pa 1976)* **33**:E494–500
27. Chou R., Shekelle P. (2010) **Will this patient develop persistent disabling low back pain?** *JAMA* **303**:1295–1302
28. Kent P. M., Keating J. L. (2008) **Can we predict poor recovery from recent-onset nonspecific low back pain? A systematic review** *Man Ther* **13**:12–28
29. Hruschak V., Cochran G. (2018) **Psychosocial predictors in the transition from acute to chronic pain: a systematic review** *Psychol Health Med* **23**:1151–1167
30. Hartvigsen J., et al. (2018) **What low back pain is and why we need to pay attention** *Lancet* **391**:2356–2367
31. Silva F. G., et al. (2022) **No prognostic model for people with recent-onset low back pain has yet been demonstrated to be suitable for use in clinical practice: a systematic review** *J Physiother* **68**:99–109
32. Baliki M. N., et al. (2012) **Corticostriatal functional connectivity predicts transition to chronic back pain** *Nat Neurosci* **15**:1117–1119

33. Mansour A. R., et al. (2013) **Brain white matter structural properties predict transition to chronic pain** *Pain* **154**:2160–2168
34. Vachon-Preseu E., et al. (2016) **Corticolimbic anatomical characteristics predetermine risk for chronic pain** *Brain* **139**:1958–1970
35. Makary M. M., et al. (2020) **Loss of nucleus accumbens low-frequency fluctuations is a signature of chronic pain** *Proceedings of the National Academy of Sciences* <https://doi.org/10.1073/pnas.1918682117>
36. Loffler M., et al. (2022) **Corticostriatal circuits in the transition to chronic back pain: The predictive role of reward learning** *Cell Rep Med* **3**
37. Jenkins L. C., et al. (2019) **Do sensorimotor cortex activity, an individual's capacity for neuroplasticity, and psychological features during an episode of acute low back pain predict outcome at 6 months: a protocol for an Australian, multisite prospective, longitudinal cohort study** *BMJ Open* **9**
38. Davis K. D., et al. (2020) **Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities** *Nat Rev Neurol* **16**:381–400
39. Von Der Heide R. J., Skipper L. M., Klobusicky E., Olson I. R. (2013) **Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis** *Brain* **136**:1692–1707
40. Green D. M., Swets J. A. (1966) **Signal detection theory and psychophysics** :xi–455
41. Timmers I., et al. (2019) **The interaction between stress and chronic pain through the lens of threat learning** *Neurosci Biobehav Rev* **107**:641–655
42. Bishop J. H., et al. (2018) **Structural network differences in chronic musculoskeletal pain: Beyond fractional anisotropy** *NeuroImage* **182**:441–455
43. Lieberman G., et al. (2014) **White Matter Involvement in Chronic Musculoskeletal Pain** *The Journal of Pain* **15**:1110–1119
44. Thiebaut de Schotten M., et al. (2011) **Atlasing location, asymmetry and inter-subject variability of white matter tracts in the human brain with MR diffusion tractography** *Neuroimage* **54**:49–59
45. Makris N., et al. (2005) **Segmentation of Subcomponents within the Superior Longitudinal Fascicle in Humans: A Quantitative, In Vivo, DT-MRI Study** *Cerebral Cortex* **15**:854–869
46. Janelle F., Iorio-Morin C., D'amour S., Fortin D. (2022) **Superior Longitudinal Fasciculus: A Review of the Anatomical Descriptions With Functional Correlates** *Frontiers in Neurology* **13**
47. Mesulam M. M. (2000) **Principles of behavioral and cognitive neurology**
48. Amemiya K., Naito E. (2016) **Importance of human right inferior frontoparietal network connected by inferior branch of superior longitudinal fasciculus tract in corporeal awareness of kinesthetic illusory movement** *Cortex* **78**:15–30
49. Nakajima R., et al. (2017) **Damage of the right dorsal superior longitudinal fascicle by awake surgery for glioma causes persistent visuospatial dysfunction** *Scientific Reports* **7**

50. Kinoshita M., et al. (2016) **Chronic spatial working memory deficit associated with the superior longitudinal fasciculus: a study using voxel-based lesion-symptom mapping and intraoperative direct stimulation in right prefrontal glioma surgery** *Journal of Neurosurgery JNS* **125**:1024–1032
51. Vallar G., et al. (2014) **Cerebral correlates of visuospatial neglect: a direct cerebral stimulation study** *Hum Brain Mapp* **35**:1334–1350
52. Thiebaut de Schotten M., et al. (2014) **Damage to white matter pathways in subacute and chronic spatial neglect: a group study and 2 single-case studies with complete virtual "in vivo" tractography dissection** *Cereb Cortex* **24**:691–706
53. Klarborg B., et al. (2013) **Sustained attention is associated with right superior longitudinal fasciculus and superior parietal white matter microstructure in children** *Hum Brain Mapp* **34**:3216–3232
54. Makris N., et al. (2008) **Attention and executive systems abnormalities in adults with childhood ADHD: A DT-MRI study of connections** *Cereb Cortex* **18**:1210–1220
55. Konrad A., et al. (2010) **Disturbed structural connectivity is related to inattention and impulsivity in adult attention deficit hyperactivity disorder** *Eur J Neurosci* **31**:912–919
56. Thomas W., et al. (2015) **Lower white matter microstructure in the superior longitudinal fasciculus is associated with increased response time variability in adults with attention-deficit/hyperactivity disorder** *Journal of Psychiatry and Neuroscience* **40**
57. Buch E. R., et al. (2012) **Parietofrontal integrity determines neural modulation associated with grasping imagery after stroke** *Brain* **135**:596–614
58. Shiao C., Tang P.-F., Wei Y.-C., Tseng W.-Y. I., Lin T.-T. (2022) **Brain white matter correlates of learning ankle tracking using a wearable device: importance of the superior longitudinal fasciculus II** *Journal of NeuroEngineering and Rehabilitation* **19**
59. Goossens N., Janssens L., Brumagne S. (2019) **Changes in the Organization of the Secondary Somatosensory Cortex While Processing Lumbar Proprioception and the Relationship With Sensorimotor Control in Low Back Pain** *The Clinical Journal of Pain* **35**
60. Naito E., Morita T., Amemiya K. (2016) **Body representations in the human brain revealed by kinesthetic illusions and their essential contributions to motor control and corporeal awareness** *Neuroscience research* **104**:16–30
61. Morita T., et al. (2017) **Self-face recognition shares brain regions active during proprioceptive illusion in the right inferior fronto-parietal superior longitudinal fasciculus III network** *Neuroscience* **348**:288–301
62. Tong M. H., et al. (2017) **Is There a Relationship Between Lumbar Proprioception and Low Back Pain? A Systematic Review With Meta-Analysis** *Arch Phys Med Rehabil* **98**:120–136
63. Lin J., Halaki M., Rajan P., Leaver A. (2019) **Relationship Between Proprioception and Pain and Disability in People With Non-Specific Low Back Pain: A Systematic Review With Meta-Analysis** *Spine* **44**

64. Ghamkhar L., Kahlaee A. H. (2019) **Pain and Pain-Related Disability Associated With Proprioceptive Impairment in Chronic Low Back Pain Patients: A Systematic Review** *J Manipulative Physiol Ther* **42**:210–217
65. Tsay A., Allen T. J., Proske U., Giummarra M. J. (2015) **Sensing the body in chronic pain: A review of psychophysical studies implicating altered body representation** *Neuroscience & Biobehavioral Reviews* **52**:221–232
66. Schwoebel J., Friedman R., Duda N., Coslett H. B. (2001) **Pain and the body schema: Evidence for peripheral effects on mental representations of movement** *Brain* **124**:2098–2104
67. Gilpin H. R., Moseley G. L., Stanton T. R., Newport R. (2014) **Evidence for distorted mental representation of the hand in osteoarthritis** *Rheumatology* **54**:678–682
68. Flor H., Nikolajsen L., Staehelin Jensen T. (2006) **Phantom limb pain: a case of maladaptive CNS plasticity?** *Nat Rev Neurosci* **7**:873–881
69. Moseley G. L., Flor H. (2012) **Targeting cortical representations in the treatment of chronic pain: a review** *Neurorehabil Neural Repair* **26**:646–652
70. Bultitude J. H., Rafal R. D. (2010) **Derangement of body representation in complex regional pain syndrome: report of a case treated with mirror and prisms** *Experimental Brain Research* **204**:409–418
71. Tanaka S., et al. (2021) **Identifying participants with knee osteoarthritis likely to benefit from physical therapy education and exercise: A hypothesis-generating study** *Eur J Pain* **25**:485–496
72. Shen W., et al. (2019) **Visual network alterations in brain functional connectivity in chronic low back pain: A resting state functional connectivity and machine learning study** *NeuroImage: Clinical* **22**
73. Zhang Z., et al. (2018) **Mapping population-based structural connectomes** *Neuroimage* **172**:130–145
74. Lee J. J., et al. (2021) **A neuroimaging biomarker for sustained experimental and clinical pain** *Nat Med* **27**:174–182
75. Ling J., et al. (2012) **Head injury or head motion? Assessment and quantification of motion artifacts in diffusion tensor imaging studies** *Hum Brain Mapp* **33**:50–62
76. Bucolo M., et al. (2022) **Cortical networks underlying successful control of nociceptive processing using real-time fMRI** *Frontiers in Pain Research* **3**
77. Kandić M., Moliadze V., Andoh J., Flor H., Nees F. (2021) **Brain Circuits Involved in the Development of Chronic Musculoskeletal Pain: Evidence From Non-invasive Brain Stimulation** *Frontiers in Neurology* **12**
78. Treede R.-D. (2018) **The International Association for the Study of Pain definition of pain: as valid in 2018 as in 1979, but in need of regularly updated footnotes** *Pain Rep* **3**:e643–e643
79. Dworkin R. H., et al. (2005) **Core outcome measures for chronic pain clinical trials: IMMPACT recommendations** *Pain* **113**:9–19

80. Flor H., Rudy T. E., Birbaumer N., Streit B., Schugens M. M. (1990) **Zur Anwendbarkeit des West Haven-Yale Multidimensional Pain Inventory im deutschen Sprachraum** *Der Schmerz* **4**:82–87
81. Smith S. M., et al. (2006) **Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data** *Neuroimage* **31**:1487–1505
82. Smith S. M., et al. (2004) **Advances in functional and structural MR image analysis and implementation as FSL** *Neuroimage* **23**:208–219
83. Andersson M. J. JLR, Smith S (2007) **Non-linear optimisation** *FMRIB Analysis Group Technical Reports*
84. Andersson M. J. JLR, Smith S (2007) **M. J. JLR Andersson, S Smith, Non-Linear registration aka Spatial Normalisation FMRIB Technical Report TR07JA2. (2007).**
85. Rueckert D., et al. (1999) **Nonrigid registration using free-form deformations: application to breast MR images** *IEEE Trans Med Imaging* **18**:712–721
86. Winkler A. M., Ridgway G. R., Webster M. A., Smith S. M., Nichols T. E. (2014) **Permutation inference for the general linear model** *Neuroimage* **92**:381–397
87. Smith S. M., Nichols T. E. (2009) **Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference** *Neuroimage* **44**:83–98
88. Desikan R. S., et al. (2006) **An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest** *Neuroimage* **31**:968–980
89. Fortin J. P., et al. (2017) **Harmonization of multi-site diffusion tensor imaging data** *Neuroimage* **161**:149–170

Article and author information

Mina Mišić

Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany;

For correspondence: mina.kandic@zi-mannheim.de

ORCID iD: [0000-0003-1754-8681](https://orcid.org/0000-0003-1754-8681)

Noah Lee

Department of Psychiatry, University of Rochester Medical Center, 14642 Rochester, NY, USA;

Francesca Zidda

Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany;

ORCID iD: [0000-0003-2507-0542](https://orcid.org/0000-0003-2507-0542)

Kyungjin Sohn

Department of Statistics and Operations Research, University of North Carolina, 27599 Chapel Hill, NC, USA;

Katrin Usai

Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany;

Martin Löffler

Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany;; Department of Experimental Psychology, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany;

Md Nasir Uddin

Department of Neurology, University of Rochester Medical Center, 14642 Rochester, NY, USA;

Arsalan Farooqi

Department of Psychiatry, University of Rochester Medical Center, 14642 Rochester, NY, USA;

Giovanni Schifitto

Department of Neurology, University of Rochester Medical Center, 14642 Rochester, NY, USA;

Zhengwu Zhang

Department of Statistics and Operations Research, University of North Carolina, 27599 Chapel Hill, NC, USA;

ORCID ID: [0000-0002-9047-8838](https://orcid.org/0000-0002-9047-8838)

Frauke Nees

Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany;; Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig Holstein, Kiel University, 24105 Kiel, Germany;

Paul Geha

Department of Psychiatry, University of Rochester Medical Center, 14642 Rochester, NY, USA;

ORCID ID: [0000-0002-0537-7216](https://orcid.org/0000-0002-0537-7216)

Herta Flor

Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany;

Copyright

© 2024, Mišić et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editors

Reviewing Editor

Markus Ploner

Technische Universität München, Munich, Germany

Senior Editor

Christian Büchel

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Reviewer #1 (Public Review):

Summary:

In this paper, Misić et al showed that white matter properties can be used to classify subacute back pain patients that will develop persisting pain.

Strengths:

Compared to most previous papers studying associations between white matter properties and chronic pain, the strength of the method is to perform a prediction in unseen data. Another strength of the paper is the use of three different cohorts. This is an interesting paper that provides a valuable contribution to the field.

Weaknesses:

The authors imply that their biomarker could outperform traditional questionnaires to predict pain: "While these models are of great value showing that few of these variables (e.g. work factors) might have significant prognostic power on the long-term outcome of back pain and provide easy-to-use brief questionnaires-based tools, (21, 25) parameters often explain no more than 30% of the variance (28-30) and their prognostic accuracy is limited.(31)". I don't think this is correct; questionnaire-based tools can actually achieve far greater prediction than their model in about half a million individuals from the UK Biobank (Tanguay-Sabourin et al., A prognostic risk score for the development and spread of chronic pain, *Nature Medicine* 2023).

Moreover, the main weakness of this study is the sample size. It remains small despite having 3 cohorts. This is problematic because results are often overfitted in such a small sample size brain imaging study, especially when all the data are available to the authors at the time of training the model (Poldrack et al., Scanning the horizon: towards transparent and reproducible neuroimaging research, *Nature Reviews in Neuroscience* 2017). Thus, having access to all the data, the authors have a high degree of flexibility in data analysis, as they can retrain their model any number of times until it generalizes across all three cohorts. In this case, the testing set could easily become part of the training making it difficult to assess the real performance, especially for small sample size studies.

Even if the performance was properly assessed, their models show AUCs between 0.65-0.70, which is usually considered as poor, and most likely without potential clinical use. Despite this, their conclusion was: "This biomarker is easy to obtain (~10 min 18 of scanning time) and opens the door for translation into clinical practice." One may ask who is really willing to use an MRI signature with a relatively poor performance that can be outperformed by self-report questionnaires?

Overall, these criticisms are more about the wording sometimes used and the inference they made. I think the strength of the evidence is incomplete to support the main claims of the paper.

Despite these limitations, I still think this is a very relevant contribution to the field. Showing predictive performance through cross-validation and testing in multiple cohorts is not an easy task and this is a strong effort by the team. I strongly believe this approach is the right one and I believe the authors did a good job.

Minor points:

Methods:

I get the voxel-wise analysis, but I don't understand the methods for the structural connectivity analysis between the 88 ROIs. Have the authors run tractography or have they used a predetermined streamlined form of 'population-based connectome'? They report that models of AUC above 0.75 were considered and tested in the Chicago dataset, but we have no information about what the model actually learned (although this can be tricky for decision tree algorithms).

Minor:

What results are shown in Figure 7? It looks more descriptive than the actual results.

<https://doi.org/10.7554/eLife.96312.1.sa2>

Reviewer #2 (Public Review):

The present study aims to investigate brain white matter predictors of back pain chronicity. To this end, a discovery cohort of 28 patients with subacute back pain (SBP) was studied using white matter diffusion imaging. The cohort was investigated at baseline and one-year follow-up when 16 patients had recovered (SBPr) and 12 had persistent back pain (SBPp). A comparison of baseline scans revealed that SBPr patients had higher fractional anisotropy values in the right superior longitudinal fasciculus (SLF) than SBPp patients and that FA values predicted changes in pain severity. Moreover, the FA values of SBPr patients were larger than those of healthy participants, suggesting a role of FA of the SLF in resilience to chronic pain. These findings were replicated in two other independent datasets. The authors conclude that the right SLF might be a robust predictive biomarker of CBP development with the potential for clinical translation.

Developing predictive biomarkers for pain chronicity is an interesting, timely, and potentially clinically relevant topic. The paradigm and the analysis are sound, the results are convincing, and the interpretation is adequate. A particular strength of the study is the discovery-replication approach with replications of the findings in two independent datasets.

The following revisions might help to improve the manuscript further.

- Definition of recovery. In the New Haven and Chicago datasets, SBPr and SBPp patients are distinguished by reductions of >30% in pain intensity. In contrast, in the Mannheim dataset, both groups are distinguished by reductions of >20%. This should be harmonized. Moreover, as there is no established definition of recovery (reference 79 does not provide a clear criterion), it would be interesting to know whether the results hold for different definitions of recovery. Control analyses for different thresholds could strengthen the robustness of the findings.
- Analysis of the Chicago dataset. The manuscript includes results on FA values and their association with pain severity for the New Haven and Mannheim datasets but not for the Chicago dataset. It would be straightforward to show figures like Figures 1 - 4 for the Chicago dataset, as well.
- Data sharing. The discovery-replication approach of the present study distinguishes the present from previous approaches. This approach enhances the belief in the robustness of the findings. This belief would be further enhanced by making the data openly available. It would be extremely valuable for the community if other researchers could reproduce and replicate the findings without restrictions. It is not clear why the fact that the studies are ongoing prevents the unrestricted sharing of the data used in the present study.

Reviewer #3 (Public Review):**Summary:**

Authors suggest a new biomarker of chronic back pain with the option to predict the result of treatment. The authors found a significant difference in a fractional anisotropy measure in superior longitudinal fasciculus for recovered patients with chronic back pain.

Strengths:

The results were reproduced in three different groups at different studies/sites.

Weaknesses:

- The number of participants is still low.
- An explanation of microstructure changes was not given.
- Some technical drawbacks are presented.

<https://doi.org/10.7554/eLife.96312.1.sa0>

Author Response

We would like to thank the editorial board and the reviewers for their assessment of our manuscript and their constructive feedback that we believe will make our manuscript stronger and clearer. Please find below our provisional response to the public reviews; these responses outline our plan to address the concerns of the reviewers for a planned resubmission. Our responses are written in red.

Public Reviews:**Reviewer #1 (Public Review):****Summary:**

In this paper, Misić et al showed that white matter properties can be used to classify subacute back pain patients that will develop persisting pain.

Strengths:

Compared to most previous papers studying associations between white matter properties and chronic pain, the strength of the method is to perform a prediction in unseen data. Another strength of the paper is the use of three different cohorts. This is an interesting paper that provides a valuable contribution to the field.

We thank the reviewer for emphasizing the strength of our paper and the importance of validation on multiple unseen cohorts.

Weaknesses:

The authors imply that their biomarker could outperform traditional questionnaires to predict pain: "While these models are of great value showing that few of these variables (e.g. work factors) might have significant prognostic power on the long-term outcome of back pain and provide easy-to-use brief questionnaires-based tools, (21, 25) parameters often explain no more than 30% of the variance (28-30) and their prognostic accuracy is limited.(31)". I don't think this is correct; questionnaire-based tools can achieve far

greater prediction than their model in about half a million individuals from the UK Biobank (Tanguay-Sabourin et al., A prognostic risk score for the development and spread of chronic pain, Nature Medicine 2023).

We agree with the reviewer that we might have under-estimated the prognostic accuracy of questionnaire-based tools, especially, the strong predictive accuracy shown by Tanguay-Sabourin 2023. In the revised version, we will change both the introduction and the discussion to reflect the the questionnaires based prognostic accuracy reported in the seminal work by TanguaySabourin. We do note here, however, that the latter paper while very novel is unique in showing the power of questionnaires. In addition, the questionnaires we have tested in our cohort did not show any baseline differences suggestive of prognostic accuracy.

Moreover, the main weakness of this study is the sample size. It remains small despite having 3 cohorts. This is problematic because results are often overfitted in such a small sample size brain imaging study, especially when all the data are available to the authors at the time of training the model (Poldrack et al., Scanning the horizon: towards transparent and reproducible neuroimaging research, Nature Reviews in Neuroscience 2017). Thus, having access to all the data, the authors have a high degree of flexibility in data analysis, as they can retrain their model any number of times until it generalizes across all three cohorts. In this case, the testing set could easily become part of the training making it difficult to assess the real performance, especially for small sample size studies.

The reviewer raises a very important point of limited sample size and of the methodology intrinsic of model development and testing. We acknowledge the small sample size in the “Limitations” section of the discussion. In the resubmission, we will acknowledge the degree of flexibility that is afforded by having access to all the data at once. However, we will also note that our SLF-FA based model is a simple cut-off approach that does not include any learning or hidden layers and that the data obtained from Open Pain were never part of the “training” set at any point at either the New Haven or the Mannheim site. Regarding our SVC approach we follow standard procedures for machine learning where we never mix the training and testing sets. The models are trained on the training data with parameters selected based on crossvalidation within the training data. Therefore, no models have ever seen the test data set. The model performances we reported reflect the prognostic accuracy of our model. Finally, as discussed by Spisak et al., 1 the key determinant of the required sample size in predictive modeling is the “ true effect size of the brain-phenotype relationship” which we think is the determinant of the replication we observe in this study. As such the effect size in the New Haven and Mannheim data is Cohen’s $d > 1$.

Even if the performance was properly assessed, their models show AUCs between 0.65-0.70, which is usually considered as poor, and most likely without potential clinical use. Despite this, their conclusion was: "This biomarker is easy to obtain (~10 min 18 of scanning time) and opens the door for translation into clinical practice." One may ask who is really willing to use an MRI signature with a relatively poor performance that can be outperformed by self-report questionnaires?

The reviewer is correct, the model performance is poor to fair which limits its usefulness for clinical translation. We wanted to emphasize that obtaining diffusion images can be done in a short period of time and, hence, as such models predictive accuracy improves, clinical translation becomes closer to reality. In addition, our findings are based on old diffusion data and limited sample size coming from different sites and different acquisition sequences. This by itself would limit the accuracy especially that evidence shows that sample size affect also model performance (i.e. testing AUC)¹. In the revision, we will re-word the sentence

mentioned by the reviewer to reflect the points discussed here. This also motivates us to collect a more homogeneous and larger sample.

Overall, these criticisms are more about the wording sometimes used and the inference they made. I think the strength of the evidence is incomplete to support the main claims of the paper.

Despite these limitations, I still think this is a very relevant contribution to the field. Showing predictive performance through cross-validation and testing in multiple cohorts is not an easy task and this is a strong effort by the team. I strongly believe this approach is the right one and I believe the authors did a good job.

We thank the reviewer for acknowledging that our effort and approach were the right ones.

Minor points:

Methods:

I get the voxel-wise analysis, but I don't understand the methods for the structural connectivity analysis between the 88 ROIs. Have the authors run tractography or have they used a predetermined streamlined form of 'population-based connectome'? They report that models of AUC above 0.75 were considered and tested in the Chicago dataset, but we have no information about what the model actually learned (although this can be tricky for decision tree algorithms).

We apologize for the lack of clarity; we did run tractography and we did not use a predetermined streamlined form of the connectome. We will clarify this point in the methods section.

Finding which connections are important for the classification of SBPr and SBPp is difficult because of our choices during data preprocessing and SVC model development: (1) preprocessing steps which included TNPCA for dimensionality reduction, and regressing out the confounders (i.e., age, sex, and head motion); (2) the harmonization for effects of sites; and (3) the Support Vector Classifier which is a hard classification model². Such models cannot tell us the features that are important in classifying the groups. Our model is considered a black-box predictive model like neural networks.

Minor:

What results are shown in Figure 7? It looks more descriptive than the actual results.

The reviewer is correct; Figure 7 and supplementary Figure 4 are both qualitatively illustrating the shape of the SLF.

Reviewer #2 (Public Review):

The present study aims to investigate brain white matter predictors of back pain chronicity. To this end, a discovery cohort of 28 patients with subacute back pain (SBP) was studied using white matter diffusion imaging. The cohort was investigated at baseline and one-year follow-up when 16 patients had recovered (SBPr) and 12 had persistent back pain (SBPp). A comparison of baseline scans revealed that SBPr patients had higher fractional anisotropy values in the right superior longitudinal fasciculus SLF than SBPp patients and that FA values predicted changes in pain severity. Moreover, the FA values of SBPr patients were larger than those of healthy participants, suggesting a role of FA of the SLF in resilience to chronic pain. These findings were replicated in two

other independent datasets. The authors conclude that the right SLF might be a robust predictive biomarker of CBP development with the potential for clinical translation.

Developing predictive biomarkers for pain chronicity is an interesting, timely, and potentially clinically relevant topic. The paradigm and the analysis are sound, the results are convincing, and the interpretation is adequate. A particular strength of the study is the discovery-replication approach with replications of the findings in two independent datasets.

We thank reviewer 2 for pointing to the strength of our study.

The following revisions might help to improve the manuscript further.

Definition of recovery. In the New Haven and Chicago datasets, SBPr and SBPp patients are distinguished by reductions of >30% in pain intensity. In contrast, in the Mannheim dataset, both groups are distinguished by reductions of >20%. This should be harmonized. Moreover, as there is no established definition of recovery (reference 79 does not provide a clear criterion), it would be interesting to know whether the results hold for different definitions of recovery. Control analyses for different thresholds could strengthen the robustness of the findings.

The reviewer raises an important point regarding the definition of recovery. To address the reviewers concern we will add a supplementary figure showing the results in the Mannheim data set if a 30% reduction is used as a recovery criterion. We would like to emphasize here several points that support the use of different recovery thresholds between New Haven and Mannheim. The New Haven primary pain ratings relied on visual analogue scale (VAS) while the Mannheim data relied on the German version of the West-Haven-Yale Multidimensional Pain Inventory. In addition, the Mannheim data was pre-registered with a definition of recovery at 20% and is part of a larger sub-acute to chronic pain study with prior publications from this cohort using the 20% cut-off³. Finally, a more recent consensus publication⁴ from IMMPACT indicates that a change of at least 30% is needed for a moderate improvement in pain on the 0-10 Numerical Rating Scale but that this percentage depends on baseline pain levels.

Analysis of the Chicago dataset. The manuscript includes results on FA values and their association with pain severity for the New Haven and Mannheim datasets but not for the Chicago dataset. It would be straightforward to show figures like Figures 1 - 4 for the Chicago dataset, as well.

We welcome the reviewer's suggestion; we will therefore add these analyses to the results section of our manuscript upon resubmission

Data sharing. The discovery-replication approach of the present study distinguishes the present from previous approaches. This approach enhances the belief in the robustness of the findings. This belief would be further enhanced by making the data openly available. It would be extremely valuable for the community if other researchers could reproduce and replicate the findings without restrictions. It is not clear why the fact that the studies are ongoing prevents the unrestricted sharing of the data used in the present study.

Reviewer #3 (Public Review):

Summary:

Authors suggest a new biomarker of chronic back pain with the option to predict the result of treatment. The authors found a significant difference in a fractional anisotropy

measure in superior longitudinal fasciculus for recovered patients with chronic back pain.

Strengths:

The results were reproduced in three different groups at different studies/sites.

Weaknesses:

The number of participants is still low.

We have discussed this point in our replies to reviewer number 1.

An explanation of microstructure changes was not given.

The reviewer points to an important gap in our discussion. While we cannot do a direct study of actual tissue micro-structure, we will explore further the changes observed in the SLF by calculating diffusivity measures and discuss possible explanations of these changes.

Some technical drawbacks are presented.

We are uncertain if the reviewer is suggesting that we have acknowledged certain technical drawbacks and expects further elaboration on our part. We kindly request that the reviewer specify what particular issues they would like us to address so that we can respond appropriately.

(1) Spisak T, Bingel U, Wager TD. Multivariate BWAS can be replicable with moderate sample sizes. *Nature* 2023;615:E4-E7.

(2) Liu Y, Zhang HH, Wu Y. Hard or Soft Classification? Large-margin Unified Machines. *J Am Stat Assoc* 2011;106:166-177.

(3) Loffler M, Levine SM, Usai K, et al. Corticostriatal circuits in the transition to chronic back pain: The predictive role of reward learning. *Cell Rep Med* 2022;3:100677.

(4) Smith SM, Dworkin RH, Turk DC, et al. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. *Pain* 2020;161:2446-2461.